Live Breaking News & Updates on Cabozantinib Versus Placebo|Page 6

Stay updated with breaking news from Cabozantinib versus placebo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting. ....

Evolving Treatments , Advanced Renal Cell Carcinoma , Novel Treatment , Renal Cell Carcinoma , Rcc Cancer , Kidney Cancer , Advanced Rcc , Metastatic Rcc , Asco 2023 , Asco Annual Meeting , Contact 03 , Ipi Nivo , Nivo Ipi , Cabo Atezo , Atezo Cabo , Tinivo 2 , Cabo Nivo , Combination Therapy , Novel Therapy , Sequencing Therapy ,

Dr Choueiri on the Investigation of ICI Continuation in Advanced RCC

Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.
....

Nancy Kohlberg , Toni Choueiri , Harvard Medical School , Lank Center , Dana Farber Cancer Institute , Kidney Cancer Program , International Strategic , International Strategic Initiatives , Genitourinary Oncology , Nancy Kohlberg Chair , Genitourinary Cancer , Onclive Tv , Metastatic Renal Cell Carcinoma , Ct04987203 , Phase 3 Tinivo 2 Trial ,

Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma

Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.
....

Briana Van , Division Of Oncology , Washington University School Of Medicine , Siteman Cancer Center , Medical Oncology , Washington University School , Van Tine , Washington University School Of Medicine In St Louis , Onclive Tv ,

Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC

The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial. ....

Bristol Myers Squibb , Tonik Choueiri , Roche Genentech , Calithera Biosciences , Bristol Myers Swuibb , International Strategic , Kidney Cancer Association , Lank Center , International Metastatic , Life Sciences , Corvus Pharmaceuticals , Analysis Group , Database Consortium , Sanofi Aventis , Infinity Pharmaceuticals , Alexion Pharmaceuticals , Navinata Health , Platformq Health , Pharma Group , Fishawack Group Of Companies , Foundation Medicine , Health Interactions , Dana Farber Cancer Institute , Gilead Sciences , Genitourinary Oncology , International Strategic Initiatives ,

#VisualAbstract: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. ....

Minute Medicine Inc , Nivolumab Ipilimumab , Renal Cell Carcinoma ,